A selective history of the therapy of Hodgkin's disease (original) (raw)

This paper discusses the historical development of curative combination chemotherapy for Hodgkin's disease, primarily focusing on advancements from 1963 to the early 1990s, highlighting the integration of chemotherapy and radiotherapy, particularly through the MOPP program at the National Cancer Institute and the ABVD regimen developed in Milan. The initial resistance in the medical community towards chemotherapy for advanced malignancies is noted, along with significant contributions made by key figures like Emil Frei and Henry Kaplan, which ultimately led to the transformation of Hodgkin's disease from a fatal to a curable condition.